SPPI News and Press, Spectrum Pharmaceuticals Inc. From 05/13/21

Spectrum Pharmaceuticals, Inc. (SPPI) Q1 2021 Earnings Conference Call May 13, 2021 16:30 ET Company Participants Kurt Gustafson - Chief Financial Officer Joe Turgeon - President and Chief Executive Officer Francois Lebel - Chief Medical Officer Conference Call Participants Maury Raycroft - J...

Image source: The Motley Fool. Spectrum Pharmaceuticals Inc (NASDAQ: SPPI) Q1 2021 Earnings Call May 13, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Spectrum Pharmaceuticals Inc (SPPI) Q1 2021 Earnings Call Tran...

Spectrum Pharmaceuticals (SPPI): Q1 Non-GAAP EPS of -$0.20 in-line; GAAP EPS of -$0.25 beats by $0.06.Cash, cash equivalents, and marketable securities of $162.9M.FDA pre-approval inspection at the ROLONTIS manufacturing facility scheduled for May 2021.Press Release For further details...

Poziotinib NDA on track for 2021 submission New poziotinib twice daily dosing (BID) data presented at AACR demonstrated improved anti-tumor activity and better tolerance FDA pre-approval inspection at the ROLONTIS ® manufacturing facility scheduled for May 202...

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced it will host a conference call to discuss the first quarter 2021 financial results and provide a corporate update on Thursday, May 13, 2021 at 4:30 p....

The following slide deck was published by Spectrum Pharmaceuticals, Inc. in conjunction with this event. For further details see: Spectrum Pharmaceuticals (SPPI) Presents At AACR Virtual Meeting 2021 - Slideshow

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Alibaba reliefShares of Alibaba (BABA) are rising in China trading after the government's decision to fine the company 4% of 2019 revenue allows it to move...

Spectrum Pharmaceuticals (SPPI) announces data update on the safety and tolerability of twice daily ((BID)) administered poziotinib in NSCLC patients with EGFR or HER2 exon 20 insertion mutations.These preliminary data, from Cohort 5 of the ZENITH20 clinical trial, continue to show improved t...

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today presented a data update on the safety and tolerability of twice daily (BID) administered poziotinib in NSCLC patients with EGFR or HER2 exon 20 insertion mutati...

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced a poster presentation on safety and tolerability of twice daily administered poziotinib in patients with EGFR or HER2 exon 20 mutations. The company w...